Recently, Eli Lilly announced that Zepbound has demonstrated superior efficacy in weight loss compared to Novo Nordisk’s Wegovy. The SURMOUNT-5 trial found that participants on Zepbound lost ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

Eli Lilly is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk being its biggest challenger. Over the past six months, Eli Lilly has earned significant wins ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly ...

Eli Lilly and Novo Nordisk are pitted against each other, but only one can be my preferred healthcare stock.. Where to invest $1,000 right now? Our analyst team just revealed what they believe are ...

Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly By Annika Kim Constantino, CNBC • Published May 19, 2025 • Updated on May 19, 2025 at 2:53 pm ...

"This solution is really focused towards clients that aren't covering it today, and what it allows us to do is one, to bring it on at a reduced price for the plan sponsor, but also capping out the ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger. Over the past six months, Eli Lilly has ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...